Add BrightSurf on Google Email

Science News for April 29, 2017


Serelaxin fails to meet primary endpoints in phase 3 RELAX-AHF-2 trial

Serelaxin, a hormone with vasodilatory effects, failed to improve cardiovascular outcomes in the phase 3 RELAX-AHF-2 trial. Despite initial promising results from previous studies, serelaxin showed no significant benefit in reducing worsening heart failure or all-cause mortality.

SourceEuropean Society of Cardiology·JournalThe Lancet·DateApr 29, 2017

Intervention reduced suicide attempts among at-risk emergency department patients

A multifaceted intervention lowered the relative risk of new suicide attempts by 20% in emergency department patients who received specialized screening, safety planning guidance, and periodic follow-up phone check-ins. Patients in the intervention group made 30% fewer total suicide attempts compared to those receiving standard ED care.

SourceBrown University·JournalJAMA Psychiatry·DateApr 29, 2017
AmScope B120C-5M Compound Microscope

AmScope B120C-5M Compound Microscope supports teaching labs and QA checks with LED illumination, mechanical stage, and included 5MP camera.